Patents Assigned to Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.
  • Modified exendins and uses thereof
    Patent number: 8716221
    Abstract: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 6, 2014
    Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.
    Inventors: Aifeng Lv, Changan Sun, Yali Wang
  • MODIFIED EXENDINS AND USES THEREOF
    Publication number: 20120196802
    Abstract: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 2, 2012
    Applicant: WUXI GRANDCHAMP PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Aifeng LV, Changan Sun, Yali Wang
  • Modified exedins and uses thereof
    Patent number: 8097586
    Abstract: Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: January 17, 2012
    Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.
    Inventors: Aifeng Lv, Changan Sun, Yali Wang
  • Modified Exedins and Uses Thereof
    Publication number: 20100009904
    Abstract: Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
    Type: Application
    Filed: January 10, 2006
    Publication date: January 14, 2010
    Applicant: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd
    Inventors: Aifeng Lv, Changan Sun, Yali Wang